Free Trial
→ JD Vance Predicts: Wall Street vs. Trump & Your Money (From Priority Gold) (Ad) Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) SEC Filings & 10K Form

Takeda Pharmaceutical logo
$13.28 -0.33 (-2.42%)
(As of 11/20/2024 ET)
Compare

Recent Takeda Pharmaceutical SEC Filings

Export to Excel
DateFilerForm TypeView
10/31/2024
5:28 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/31/2024
5:19 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/31/2024
5:21 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/26/2024
5:01 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/22/2024
7:36 PM		Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/31/2024
6:46 AM		Takeda Pharmaceutical (Filed by)
Xilio Therapeutics, Inc. (Subject)
Form SC 13G/A
07/31/2024
5:02 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/10/2024
6:12 AM		Amakawa Akiko (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:13 AM		Plump Andrew Stewart (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:13 AM		Takeda Pharmaceutical (Subject)
Weber Christophe Pierre (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:14 AM		Shannon Elaine Mary (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:15 AM		Ricci Gabriele (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:15 AM		Platford Giles Richard (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:16 AM		Kim Julie So-Young (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:16 AM		Duprey Lauren Rusckowski (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:17 AM		Pignagnoli Agosti Marcello (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:17 AM		Sequeira Ramona (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:18 AM		Bitetti Teresa Marie (Reporting)
Takeda Pharmaceutical (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
6:19 AM		Takeda Pharmaceutical (Subject)
Wozniewski Thomas Otto Claus (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2024
5:04 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2024
5:05 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/05/2024
10:28 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/02/2024
5:20 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/01/2024
5:33 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/28/2024
7:24 AM		Takeda Pharmaceutical (Subject)
Form FWP
06/28/2024
7:25 AM		Takeda Pharmaceutical (Filer)
Form 424B2
Transaction specifc information for a delayed shelf offering
06/27/2024
5:01 AM		Takeda Pharmaceutical (Filer)
Form 424B5
06/26/2024
7:26 AM		Takeda Pharmaceutical (Filer)
Form F-3ASR
06/26/2024
5:01 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2024
5:02 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/26/2024
5:07 AM		Takeda Pharmaceutical (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
06/17/2024
5:46 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/11/2024
5:23 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/10/2024
5:10 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/07/2024
5:04 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/07/2024
5:07 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/03/2024
5:45 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/03/2024
5:26 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/29/2024
5:24 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/29/2024
5:29 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/29/2024
5:29 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
“This Changes Everything” - Trump Hands Millions Massive IRS Gift (Ad)

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!
05/29/2024
5:29 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2024
5:02 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/09/2024
5:01 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/09/2024
5:02 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/09/2024
5:03 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/09/2024
5:04 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/09/2024
5:08 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/25/2024
5:04 AM		Takeda Pharmaceutical (Filer)
Form SD
Specialized Disclosure Report  
04/19/2024
5:12 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2024
5:02 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2024
5:10 AM		Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
04/01/2024
5:15 AM		Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
03/27/2024
5:34 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/09/2024
5:03 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2024
8:36 AM		BlackRock Inc. (Filed by)
Takeda Pharmaceutical (Subject)
Form SC 13G/A
02/05/2024
5:24 AM		Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
Takeda Pharmaceutical (Subject)
Form SC 13G/A
02/02/2024
5:16 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/01/2024
5:18 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/01/2024
5:06 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/25/2024
5:13 AM		Phathom Pharmaceuticals, Inc. (Issuer)
Takeda Pharmaceutical (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/25/2024
5:11 AM		Phathom Pharmaceuticals, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13D/A
01/19/2024
5:03 AM		Equillium, Inc. (Subject)
Takeda Pharmaceutical (Filed by)
Form SC 13G
01/16/2024
5:01 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/14/2023
5:01 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/30/2023
5:01 AM		Takeda Pharmaceutical (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (NYSE:TAK) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners
Missed Nvidia? Watch this ASAP
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...
Brownstone Research | Sponsored
Musk’s new company could top a trillion?
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...
Paradigm Press | Sponsored
Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...
Timothy Sykes | Sponsored
Unveiled: NVIDIA’s "Secret Royalty" Program
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time N...
Behind the Markets | Sponsored
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...
Stansberry Research | Sponsored
24/7 Automated Profits in Crypto
The 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...
Crypto Swap Profits | Sponsored
Trump Wins… But Elon Says Get Ready to Brace
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...
Genesis Gold Group | Sponsored
But another coin could soar even higher …
Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...
Weiss Ratings | Sponsored